GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that the U.S. Food and Drug Administration (FDA) has approved Benlysta® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
FDA accepts new drug application for investigational compound Dapagliflozin
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for dapagliflozin, an investigational compound for the treatment of adults with type 2 diabetes mellitus.
Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares
- Details
- Category: Genzyme
Genzyme Corporation (NASDAQ: GENZ) announced that its Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer to purchase all outstanding shares of Genzyme common stock for $74.00 and one contingent value right, per share.
Pfizer Announces Primary Endpoints Met in Second Phase 3 Clinical Trial of Tofacitinib
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) announced that the ORAL Sync Phase 3 study (A3921046) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis (RA), met its primary endpoints
Bayer extends support to fight Chagas disease
- Details
- Category: Bayer
Bayer HealthCare today signed an extension of its agreement with the World Health Organization (WHO) to fight Chagas disease, a deadly and neglected tropical disease (NTD). The five-year extension will come into effect in April 2012, when the previous agreement signed in 2007 had been set to expire.
Breakaway From Cancer(R) Launches Newly-Enhanced Website
- Details
- Category: Amgen
As part of its ongoing mission to serve cancer patients, Amgen's Breakaway from Cancer(R) initiative announced the launch of its enhanced website that provides cancer patients, survivors, and caregivers a 'one-stop shop' of essential resources spanning cancer prevention, education, patient care, advocacy, and financial support.
Breaking the Taboo Associated with Hemorrhoidal Disease
- Details
- Category: Bayer
Experts assume that more than 50 percent of Americans over the age of 50 have had symptoms related to hemorrhoidal disease at some point in their lives(1).
More Pharma News ...
- Nycomed well positioned in emerging markets
- Roche Annual General Meeting: dividend raised by 10%
- Nycomed's novel COPD therapy roflumilast receives FDA approval
- Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program
- Results Published in The Lancet Demonstrate Superiority of XGEVA(TM) (Denosumab)
- Bayer and Onyx Initiate Phase III Trial of Nexavar® in Combination with Chemotherapy
- Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011